Investor Update

Basel, 15 April 2010

Excellent growth in first quarter of 2010

- Group sales up 9% in local currencies to 12.2 billion Swiss francs in first three months (+6% in Swiss francs, +15% in US dollars).
- Both divisions continue to outgrow their respective markets in 2010 [1].
- Roche confirms full-year outlook.

Sales in millions of CHF	Three months ended 31 March		% change		
	2010	2009	In CHF	In LC*	In USD
Pharmaceuticals Division	9,727	9,216	+6	+10	+15
United States	3,647	3,586	+2	+10	+10
Western Europe	2,597	2,532	+3	+4	+11
Japan	988	1,139	-13	-9	-6
International**	2,495	1,959	+27	+25	+38
Diagnostics Division	2,518	2,361	+7	+9	+16
Roche Group	12,245	11,577	+6	+9	+15

*LC= local currencies
International: **Asia–Pacific, CEMAI (Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent), **Latin America, Canada, Others**
See appendix to this media release for details of quarterly sales growth

Pharmaceuticals Division posts double-digit growth in first quarter
- Pharma sales grow 10% (6% in Swiss francs, 15% in US dollars)
- Continued strong growth of oncology portfolio, increasing 12% in local currencies; sales of leading cancer medication Avastin advance 18%.
- Promising US launch of Actemra for rheumatoid arthritis
- Rituxan approved in US for chronic lymphocytic leukemia, the most common form of adult leukemia
- US marketing application for T–DM1 for advanced HER2-positive breast cancer to be brought forward to 2010, based on strong phase II results

Diagnostics Division continues to significantly outperform the market
- Divisional sales grow 9% (7% in Swiss francs, 16% in US dollars), again substantially ahead of the global market, driven by Professional Diagnostics, Diabetes Care and Applied Science
- Continued strong uptake of recently launched products in Diabetes Care (Accu-Chek Mobile, Accu-Chek Combo) as well as other business areas (cobas 8000, cobas 4800 and xCELLigence systems)

Barring unforeseen events.
[1] Unless otherwise stated, all growth rates are in local currencies

F. Hoffmann-La Roche Ltd
4070 Basel
Switzerland
Investor Relations
email:
investor.relations@roche.com§
Tel. +41-(0)61-688 88 80
Fax +41-(0)61-691 00 14
http://ir.roche.com

Commenting on the Group's first-quarter sales figures, Roche CEO Severin Schwan said: 'With sales advancing 9%, Roche is off to a very good start in 2010. Both divisions continued to outgrow their respective markets. We are thus fully on track for 2010.' Referring to Roche's strong late-stage pipeline, Schwan added: 'I am very pleased that, after discussions with the FDA, we are now planning to submit a US marketing application for our innovative breast cancer treatment T–DM1 this year, based on strong phase II data in women who have not responded to prior treatments.'

Roche Group

Strong sales growth in first quarter

The Roche Group sustained its strong sales growth in the first three months of 2010. Group sales grew 9% in local currencies (6% in Swiss francs; 15% in US dollars) to 12.2 billion Swiss francs. The Pharmaceuticals Division's sales increased 10% in local currencies (6% in Swiss francs; 15% in US dollars) to 9.7 billion Swiss francs, maintaining its above-market growth. The Diagnostics Division also maintained its above-market growth, with sales increasing 9% in local currencies (7% in Swiss francs; 16% in US dollars) to 2.5 billion Swiss francs.

At its Investor Day in March, Roche provided an in-depth review of its near- and long-term growth opportunities. Roche plans to introduce at least six new medicines by the end 2014. Of the 61 new molecular entities (NMEs) in the Group's R&D pipeline, ten are currently in late-stage development, and Roche plans to increase this to as many as 13 NMEs by year end. The Group's late-stage pipeline also comprises more than 35 new indications for existing products. Roche is set to strengthen its global leadership position in oncology and to expand in therapeutic areas such as metabolism, inflammation and diseases of the central nervous system.

In the first quarter Roche continued to pay down the debt raised to finance the Genentech transaction: 3 billion US dollars and 1.5 billion Euros were repaid as scheduled.

Outlook

Based on its first-quarter sales, Roche confirms its full-year outlook for 2010. Barring unforeseen events, Roche expects sales in 2010 for the Pharmaceuticals Division and for the Group to increase in the mid-single-digit range in local currencies (excluding Tamiflu). In the Diagnostics Division, full-year sales are expected to grow significantly ahead of the market. Despite an anticipated decrease in Tamiflu sales from 3.2 to

1.2 billion Swiss Francs, Roche is aiming to achieve double-digit Core Earnings per Share growth at constant exchange rates. In addition, by the end of the year Roche expects to have repaid a quarter of the debt raised to finance the Genentech transaction.

Pharmaceuticals Division

Sales continue to grow significantly faster than the global market

Top-selling pharmaceuticals Jan–Mar 2010	Total		US		Western Europe		Japan		International**	
	CHF m	%*	CHF m	%*	CHF m	%*	CHF m	%*	CHF m	%*
Avastin	1,666	18	845	13	484	18	120	53	217	25
MabThera/ Rituxan	1,606	13	763	8	442	14	53	6	348	27
Herceptin	1,417	11	408	14	570	12	67	-14	372	12
Tamiflu	517	32	170	1099	3	-97	126	-47	218	620
Pegasys	441	15	102	9	99	-4	26	-12	214	36
CellCept	357	-28	83	-65	123	5	12	12	139	5
Xeloda	352	23	123	25	81	10	27	81	121	21
NeoRecormon/ Epogin	339	-8	-	-	141	-17	102	-7	96	6
Lucentis	327	27	327	27	-	-	-	-	-	-
Tarceva	326	6	120	2	116	3	17	19	73	16

* Local growth rates versus YTD March 2009
** Asia–Pacific, CEMAI (Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent), Latin America, Canada, Others

Sales by the Pharmaceuticals Division in the first three months rose 10% in local currencies (6% in Swiss francs, 15% in US dollars) to 9.7 billion Swiss francs, significantly faster than the global pharmaceuticals market, with the growth of key products more than offsetting lower sales of CellCept and NeoRecormon. The main sales drivers were Avastin, MabThera/Rituxan, Herceptin, Tamiflu, Lucentis, Xeloda and Pegasys. Excluding Tamiflu, the division's sales increased 8%.

Regional sales overview

First-quarter sales outpaced the market in all regions except Japan. Growth in Western Europe was driven mainly by Avastin, Herceptin, MabThera, Actemra and Mircera, more than compensating for significantly lower sales of Tamiflu and NeoRecormon. The main sales drivers in the United States were Tamiflu, Avastin, Lucentis, Rituxan, Herceptin and Xeloda. Solid sales growth in the International region was fuelled by increased sales of Avastin, MabThera, Pegasys and Tamiflu. In Japan strong growth of Avastin, Actemra and

Xeloda was outweighed by a significant decline in sales of Tamiflu and destocking by wholesalers in anticipation of revised National Health Insurance reimbursement prices, which come into effect in April.

Sales review — selected key products

Sales of **Avastin** (bevacizumab), for advanced colorectal, breast, lung and kidney cancer, and for relapsed glioblastoma (a type of brain tumour), rose 18% to 1.7 billion Swiss francs. Sustained growth in all regions continued to be driven by uptake in colorectal, breast and/or lung cancer, the product's largest indications. Apart from the US, where penetration rates are already high, patient share in all three indications continues to grow strongly. Sales by Chugai in Japan remain particularly strong, driven by sustained growth in colorectal cancer and helped further by the product's launch for the treatment of non-small cell lung cancer in November.

Overall sales (oncology and autoimmune diseases) of **MabThera/Rituxan** (rituximab), for non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and rheumatoid arthritis (RA), rose 13% to 1.6 billion Swiss francs. Sustained growth in the oncology segment was driven by strong uptake in CLL worldwide, as well as continued penetration in NHL in countries of the International region. Sales growth in the rheumatoid arthritis segment was driven primarily by increased use of MabThera/Rituxan in patients with an inadequate response to one or more tumour necrosis factor inhibitors.

Global sales of **Herceptin** (trastuzumab), for HER2-positive breast cancer, advanced 11% to 1.4 billion Swiss francs in the first quarter. Growth was driven by continuing penetration in the early and metastatic disease settings. Sales are expected to be helped further by the rollout of Herceptin in the newly approved stomach cancer indication in the EU.

The robust sales performance of **Xeloda** (capecitabine), for colorectal, stomach and breast cancer, which grew 23% to 352 million Swiss francs, was driven primarily by strong gains in the United States, China and Japan. Growth in China is being fuelled mainly by use of the medicine in advanced stomach cancer, while sales in Japan continued to benefit from an expanded metastatic colorectal cancer indication approved in 2009.

Sales of **Tarceva** (erlotinib), for advanced lung and pancreatic cancer, increased 6% to 326 million Swiss francs in the first quarter, driven primarily by strong growth in the International region. Solid double-digit sales growth in Japan reflects continuing market penetration.

First-quarter sales of the antiinfluenza medicine **Tamiflu** (oseltamivir) totalled 517 million Swiss francs, a rise of 32% over the relatively low baseline of the prior-year period (401 million francs). Following the exceptional demand seen in the last three quarters of 2009 due to the worldwide influenza A (H1N1) pandemic, global sales of Tamiflu have slowed significantly since December. Roche has now filled the bulk of government pandemic orders received in 2009 and early 2010. In addition, according to the latest World Health Organization and US Centers for Disease Control updates, the current wave of the H1N1 pandemic has passed its peak in Europe and North America. Barring unforeseen events, Roche expects full-year sales of Tamiflu of about 1.2 billion Swiss francs in 2010.

Sales of **Pegasys** (peginterferon alfa-2a), for hepatitis B and C, rose 15% to 441 million Swiss francs. Growth is being driven by market expansion in emerging countries and increasing market share globally. Pegasys is benefiting from the publication of new studies demonstrating the medicine's superiority over other hepatitis C treatment options, as well as increased use in hepatitis B.

US sales of **Lucentis** (ranibizumab), for wet age-related macular degeneration (AMD), were up 27% compared with the first quarter of 2009 to 327 million Swiss francs. Robust growth throughout the quarter was driven primarily by an increase in the total number of patients receiving Lucentis.

Sales of the novel rheumatoid arthritis (RA) medicine **RoActemra** (tocilizumab, known as **Actemra** outside Europe) continued to develop very well in the first quarter of 2010, supported by further growth in the 2009 launch markets and by the ongoing rollout in additional countries, notably the US and France. Global sales totalled 66 million Swiss francs in the first quarter, an increase of 236% over the year-earlier period. In the US, where Actemra has been available since mid-January, the initial response from physicians and patients has been very encouraging. Market uptake in Japan also remained strong. Here and in other markets where this indication is approved, doctors are already using the medicine as a first-line biologic treatment in many RA patients.

Product development highlights

The major regulatory approvals gained and important marketing applications filed by the Pharmaceuticals Division in the first quarter of 2010 are summarised in the tables below.

Major regulatory filings in Q1 2010[1]

Product	Clinical data supporting filing	Indication and/or dosage form	Country
Actemra	LITHE (2-year data)	prevention of structural joint damage and improvement of physical function in adults with moderately to severe active rheumatoid arthritis	USA
Herceptin + Xeloda	ToGA	HER2-positive advanced or recurrent gastric cancer	Japan
MabThera/Rituxan	PRIMA	maintenance treatment in previously untreated patients with advanced follicular lymphoma	EU, USA
Xeloda	XELOXA (NO16968)	adjuvant colon cancer, combination with oxaliplatin	Switzerland

[1] Includes additional indications

Major regulatory approvals in Q1 2010[1]

Product	Clinical data supporting filing	Indication and/or dosage form	Country
Actemra	OPTION, TOWARD, RADIATE, AMBITION, LITHE (6-month data)	rheumatoid arthritis signs and symptoms	USA
Avastin	AVF 2107, E3200, NO16966 (global); ARTIST (China)	first-line metastatic colorectal cancer	China
Herceptin	ToGA	HER2-positive metastatic (advanced) gastric cancer	EU
Rituxan	REACH	relapsed or refractory chronic lymphocytic leukemia	USA
	CLL-8	first-line chronic lymphocytic leukemia	USA
Xeloda	XELOXA (NO16968)	adjuvant colon cancer, combination with oxaliplatin	EU

[1] Includes additional indications

In March the US the Food and Drug Administration (FDA) confirmed that it has designated Genentech's supplemental Biologics License Application (sBLA) for **Lucentis** in the treatment of macular edema following retinal vein occlusion for priority review, with 22 June 2010 as the action date. Also in March the EU's Committee for Medicinal Products for Human Use (CHMP) recommended approval of **Tarceva** for maintenance treatment in patients with advanced non-small cell lung cancer and stable disease after initial (first-line) chemotherapy. Roche's filing was based on data from the pivotal phase III SATURN trial. A final decision by the European Commission on approval of the new indication is expected within 45 days. In January the FDA extended the review period for the application for Tarceva in this indication following submission of further data by OSI Pharmaceuticals. The anticipated action date is now 18 April.

Following discussions with the FDA, Genentech now plans to submit a US marketing application in 2010 for the novel antibody–drug conjugate T–DM1 (RG3502). The application, for approval of T–DM1 for patients with advanced metastatic HER2-positive breast cancer, will be based on the positive phase II data presented at the San Antonio Breast Cancer Symposium last December.

Roche announced initial results from phase III clinical trials with **Avastin** in ovarian, gastric and prostate cancer during the first quarter. The results of the GOG 0218 study showed that combined Avastin and chemotherapy followed by maintenance treatment with Avastin alone increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival), compared with chemotherapy alone. The AVAGAST (gastric cancer) and CALGB 90401 (prostate cancer) trials did not meet their primary endpoints of extending overall survival. Data from all three studies have been submitted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting in June.

As already announced, in March Roche and Biogen Idec decided to suspend administration of **ocrelizumab** to patients in the rheumatoid arthritis programme. This followed a recommendation by the RA and lupus programme's independent data and safety monitoring board, which concluded that the safety risk outweighs the benefits observed in RA and lupus patient populations at this time. A phase II trial with ocrelizumab in relapsing remitting multiple sclerosis is continuing.

R&D pipeline update

As of 31 March 2010 the Pharmaceuticals Division's research and development pipeline (phase I to III/registration) included 61 new molecular entities and 49 additional indications. In the first quarter of 2010 three projects entered phase I, one entered phase II and two (RG7204, aleglitazar) entered phase III development. One phase II project was discontinued. Full details of the Group's pharmaceutical R&D pipeline are available at roche.com.

Diagnostics Division

Sales continue to significantly outgrow the market

Sales January–March 2010	In millions of CHF	% change in CHF	% change in local currencies	As % of sales
Diagnostics Divsion	2,518	7	9	100
- Professional Diagnostics	1,170	8	9	46
- Diabetes Care	708	4	6	28
- Molecular Diagnostics	294	0	2	12
- Applied Science	226	15	19	9
- Tissue Diagnostics	120	13	21	5

Roche's Diagnostics Division recorded first-quarter sales of 2,518 million Swiss francs, an increase of 9% in local currencies (7% in Swiss francs). This was substantially ahead of the global market . All five business areas increased their sales in local currencies, with Professional Diagnostics, Diabetes Care and Applied Science the biggest contributors to growth. Strong uptake of the recently launched Accu-Chek Mobile (strip-free blood glucose monitoring system), Accu-Chek Combo (combined insulin pump/blood glucose monitoring system), cobas 8000 (fully automated high-throughput analyser), cobas 4800 (fully automated system for molecular diagnostics) and xCELLigence (cell analysis system) continued, combined with rollouts in additional European and Asia–Pacific markets during the first quarter. Sales grew ahead of the market in all regions: Asia–Pacific and Latin American countries continued their excellent sales development, with growth in the E7 emerging markets (Brazil, Russia, India, China, Korea, Mexico and Turkey) reaching 25%, led by China.

Professional Diagnostics' first-quarter sales rose 9% to 1,170 million Swiss francs. The immunoassay business again outpaced the market with sales growth of 16%. New placements of cobas 6000 and recent additions to the immunoassay menu were key growth drivers. The successful rollout of the cobas 8000 modular analyser continued in the EU and Asia–Pacific. Professional Diagnostics launched three new or next-generation immunoassays: in the EU and other markets that recognise CE Mark certification a pregnancy test for free β-HCG and PAPP-A to evaluate the risk of trisomy 21 (Down syndrome), and in the US market the accelerated (STAT) NT-proBNP test for the risk of heart failure and the Rubella IgM test to diagnose rubella infection in women. Sales of decentralised solutions rose 5%, led by strong demand for portable testing systems such as the CoaguChek coagulation monitors. The CoaguChek XS plus system, a point-of-care anticoagulation monitor, was granted CLIA-waived status by the FDA, allowing its use in a broader range of clinical settings.

Diabetes Care's combined sales of blood glucose (BG) monitoring systems and insulin pumps rose 6%, significantly ahead of global diabetes market, to 708 million Swiss francs. The main growth drivers were the Accu-Chek Aviva and Accu-Chek Performa BG monitoring systems, both of which posted strong double-digit sales growth. Market uptake of the newly launched Accu-Chek Mobile, the first and only strip-free BG monitoring system, has been excellent, with the product now available in twelve countries in Europe and Asia–Pacific. Sales of the insulin delivery business posted double digit growth, driven by continued strong uptake of the new Accu-Chek Combo, a combination of insulin pump and BG monitoring system, which was launched in another seven European and Asia–Pacific markets during the first quarter. As announced in April, Roche will acquire 100% of Medingo Ltd., a majority-owned subsidiary of the Elron group engaged in the development of a semi-disposable insulin patch pump. Through the acquisition Diabetes Care will broaden its portfolio of innovative insulin delivery technologies.

Molecular Diagnostics posted sales of 294 million Swiss francs (2%) in the first quarter. The slight decline in virology, which showed a very strong performance in the first quarter of 2009 due to non-recurring instrument sales in Asia–Pacific, was more than offset by substantial growth in blood screening (8%), based on the addition of new customers. Initial uptake in key markets of the cobas 4800 system, launched at the end of 2009, has been very encouraging. This system offers full automation for mid- to high-throughput testing with a current menu of dual target tests for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* and a screening and genotyping test for human papillomavirus (HPV). Preliminary data from the ATHENA trial were released in February, demonstrating the clinical utility of HPV genotyping in cervical cancer screening. Full data from the ATHENA trial with the cobas 4800 HPV test will be presented in July, with a US filing planned for mid year.

Applied Science's first-quarter sales rose 19% to 226 million Swiss francs, driven by strong demand for the MagNA Pure and LightCycler product lines for sample preparation and quantitative PCR analysis (39%), particularly in China. The microarray business grew by almost 40%, with the NimbleGen CGX-6 cytogenetics multiplex array for high-resolution analysis of chromosomal abnormalities launched worldwide, as planned. Strong growth in the cell analysis segment is being driven by CIM-Plate 16, launched at the end of 2009, which enables the study of cell migration and invasion in real time and opens up new application fields for the xCELLigence cell analysis system.

Tissue Diagnostics recorded first-quarter sales of 120 million Swiss francs, up 21%, outperforming the market in all key regions. Advanced tissue staining – immunohistochemistry (IHC) and in situ hybridisation

(ISH) – continued to be the main growth driver, reflecting a robust 17% rise in IHC and 73% rise in ISH reagent sales, along with continued excellent uptake of the BenchMark Ultra system for simultaneous IHC and ISH testing on a single platform. Tissue Diagnostics further expanded its advanced staining portfolio with the US launch of Discovery ULTRA, an automated platform for IHC and ISH in the research setting that offers significant improvements in ease of use, workflow and system flexibility.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Additional information

- Investor Update including a full set of tables: http://www.roche.com/inv-update-2010-04-15.htm
- Annual Report 2009: www.roche.com/annual_reports.htm
- Roche Pharmaceuticals pipeline: www.roche.com/pipeline.htm
- Roche Finance Info System: rofis.roche.com/dynasight/rofis.html

Roche IR Contacts:

Dr. Karl Mahler
Phone: +41 (0)61 687 85 03
e-mail: karl.mahler@roche.com

Dianne Young
Phone: +41 (0)61 688 93 56
e-mail: dianne.young@roche.com

Dr. Sabine Borngräber
Phone: +41 (0)61 688 80 27
e-mail: sabine.borngraeber@roche.com

Dr. Nicolas Dunant
Phone: +41 (0)61 687 05 17
e-mail: nicolas.dunant@roche.com

Dr. Nina Mojas
Phone: +41 (0) 61 687 13 00
e-mail: nina.mojas@roche.com

Thomas Kudsk Larsen
Phone: +1 973 235 36 55
Mobile phone: +1 973 393 53 15
e-mail: thomas_kudsk.larsen@roche.com

Nina Sachdev
Phone: +1 973 562 2793
Mobile phone: +1 973 362 5098
e-mail: nina.sachdev@roche.com

Kathee Littrell, Ph.D., R.N.
Phone: +1 650 225 1034
e-mail: littrell.kathee@gene.com

1. Sales January to March 2010 and 2009

	2010	2009	% change	
January – March	CHF m	CHF m	In CHF	In local currencies
Pharmaceuticals Division	9,727	9,216	+6	+10
United States	3,647	3,586	+2	+10
Western Europe	2,597	2,532	+3	+4
Japan	988	1,139	-13	-9
International	2,495	1,959	+27	+25
Diagnostics Division	2,518	2,361	+7	+9
Roche Group	12,245	11,577	+6	+9

2. Quarterly local sales growth by Division in 2009 and 2010

	Q2 2009 vs. Q2 2008	Q3 2009 vs. Q3 2008	Q4 2009 vs. Q4 2008	Q1 2010 vs. Q1 2009
Pharmaceuticals Division	+14	+15	+8	+10
United States	+12	+4	+4	+10
Western Europe	+7	+17	+13	+4
Japan	+16	+46	+18	-9
International	+24	+17	+4	+25
Diagnostics Division	+7	+10	+10	+9
Roche Group	+12	+14	+8	+9

3. Quarterly sales by Division in 2009 and 2010

CHF millions	Q1 2009	Q2 2009	Q3 2009	Q4 2009	Q1 2010
Pharmaceuticals Division	9,216	9,888	9,930	9,962	9,727
United States	3,586	3,930	3,641	3,648	3,647
Western Europe	2,532	2,650	2,844	2,801	2,597
Japan	1,139	1,045	1,306	1,275	988
International	1,959	2,263	2,139	2,238	2,495
Diagnostics Division	2,361	2,541	2,463	2,690	2,518
Roche Group	11,577	12,429	12,393	12,652	12,245

1. **Top 20 Pharmaceuticals Division product sales and local growth YTD March 2010 vs. YTD March 2009: US, Western Europe, Japan and International**

	Total		United States		Western Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	1,666	18%	845	13%	484	18%	120	53%	217	25%
MabThera/Rituxan	1,606	13%	763	8%	442	14%	53	6%	348	27%
Herceptin	1,417	11%	408	14%	570	12%	67	-14%	372	12%
Tamiflu	517	32%	170	1099%	3	-97%	126	-47%	218	620%
Pegasys	441	15%	102	9%	99	-4%	26	-12%	214	36%
CellCept	357	-28%	83	-65%	123	5%	12	12%	139	5%
Xeloda	352	23%	123	25%	81	10%	27	81%	121	21%
NeoRecormon/Epogin	339	-8%	-	-	141	-17%	102	-7%	96	6%
Lucentis	327	27%	327	27%	-	-	-	-	-	-
Tarceva	326	6%	120	2%	116	3%	17	19%	73	16%
Bonviva/Boniva	277	17%	144	14%	79	12%	-	-	54	33%
Valcyte/Cymevene	149	18%	70	28%	46	19%	-	-	33	-1%
Xolair	148	5%	148	5%	-	-	-	-	-	-
Pulmozyme	135	17%	75	9%	30	5%	-	-	30	78%
Activase/TNKase	110	-6%	100	-5%	-	-	-	-	10	-24%
Xenical	91	-11%	10	26%	44	5%	-	-	37	-30%
Nutropin	91	-6%	88	-6%	-	-	-	-	3	-3%
Rocephin	82	10%	2	2325%	16	-6%	13	-13%	51	20%
Neutrogin	81	-5%	-	-	-	-	81	-5%	-	-
Madopar	75	8%	-	-	27	-5%	5	0%	43	20%

2. Top 20 Pharmaceuticals Division quarterly local product sales growth

	Q2 2009 vs. Q2 2008	Q3 2009 vs. Q3 2008	Q4 2009 vs. Q4 2008	Q1 2010 vs. Q1 2009
Avastin	29%	21%	9%	18%
MabThera/Rituxan	10%	7%	0%	13%
Herceptin	10%	8%	2%	11%
Tamiflu	1048%	887%	620%	32%
Pegasys	10%	13%	-11%	15%
CellCept	-21%	-26%	-45%	-28%
Xeloda	14%	11%	-2%	23%
NeoRecormon/Epogin	-8%	-7%	-15%	-8%
Lucentis	21%	21%	34%	27%
Tarceva	7%	11%	10%	6%
Bonviva/Boniva	2%	0%	-10%	17%
Valcyte/Cymevene	6%	7%	1%	18%
Xolair	11%	9%	8%	5%
Pulmozyme	8%	8%	-1%	17%
Activase/TNKase	17%	34%	39%	-6%
Xenical	-10%	-14%	-15%	-11%
Nutropin	2%	-6%	-9%	-6%
Rocephin	2%	-2%	-19%	10%
Neutrogin	-13%	-10%	-12%	-5%
Madopar	-5%	1%	-4%	8%

3. Pharmaceuticals Division quarterly local product sales growth United States

	Q2 2009 vs. Q2 2008	Q3 2009 vs. Q3 2008	Q4 2009 vs. Q4 2008	Q1 2010 vs. Q1 2009
Avastin	22%	13%	3%	13%
MabThera/Rituxan	6%	1%	-3%	8%
Herceptin	12%	1%	5%	14%
Tamiflu	710%	99%	558%	1099%
Pegasys	4%	11%	-18%	9%
CellCept	-46%	-50%	-85%	-65%
Xeloda	12%	18%	0%	25%
NeoRecormon/Epogin	-	-	-	-
Lucentis	21%	21%	34%	27%
Tarceva	-5%	8%	17%	2%
Bonviva/Boniva	-10%	-14%	-21%	14%
Valcyte/Cymevene	8%	17%	-4%	28%
Xolair	11%	9%	8%	5%
Pulmozyme	4%	10%	4%	9%
Activase/TNKase	20%	38%	45%	-5%
Xenical	-25%	-9%	17%	26%
Nutropin	2%	-6%	-9%	-6%
Rocephin	-11%	-	1013%	2325%
Neutrogin	-	-	-	-
Madopar	-	-	-	-

4. Pharmaceuticals Division quarterly local product sales growth Western Europe

	Q2 2009 vs. Q2 2008	Q3 2009 vs. Q3 2008	Q4 2009 vs. Q4 2008	Q1 2010 vs. Q1 2009
Avastin	30%	20%	13%	18%
MabThera/Rituxan	9%	11%	8%	14%
Herceptin	3%	6%	-1%	12%
Tamiflu	1394%	Over 10000%	5532%	-97%
Pegasys	3%	-3%	-8%	-4%
CellCept	1%	1%	1%	5%
Xeloda	-3%	-2%	-7%	10%
NeoRecormon/Epogin	-18%	-17%	-20%	-17%
Lucentis	-	-	-	-
Tarceva	9%	12%	7%	3%
Bonviva/Boniva	9%	14%	3%	12%
Valcyte/Cymevene	6%	-1%	3%	19%
Xolair	-	-	-	-
Pulmozyme	11%	5%	-3%	5%
Activase/TNKase	-	-	-	-
Xenical	2%	10%	2%	5%
Nutropin	-	-	-	-
Rocephin	-12%	4%	-21%	-6%
Neutrogin	-	-	-	-
Madopar	-10%	-10%	-10%	-5%

5. Pharmaceuticals Division quarterly local product sales growth Japan

	Q2 2009 vs. Q2 2008	Q3 2009 vs. Q3 2008	Q4 2009 vs. Q4 2008	Q1 2010 vs. Q1 2009
Avastin	96%	59%	44%	53%
MabThera/Rituxan	4%	6%	0%	6%
Herceptin	42%	13%	2%	-14%
Tamiflu	Over 10000%	Over 10000%	204%	-47%
Pegasys	30%	6%	-5%	-12%
CellCept	8%	18%	9%	12%
Xeloda	27%	29%	52%	81%
NeoRecormon/Epogin	-1%	3%	0%	-7%
Lucentis	-	-	-	-
Tarceva	27%	19%	23%	19%
Bonviva/Boniva	-	-	-	-
Valcyte/Cymevene	-	-	-	-
Xolair	-	-	-	-
Pulmozyme	-	-	-	-
Activase/TNKase	-	-	-	-
Xenical	-	-	-	-
Nutropin	-	-	-	-
Rocephin	-2%	-1%	-18%	-13%
Neutrogin	-13%	-10%	-12%	-5%
Madopar	3%	3%	2%	0%

6. Pharmaceuticals Division quarterly local product sales growth International

	Q2 2009 vs. Q2 2008	Q3 2009 vs. Q3 2008	Q4 2009 vs. Q4 2008	Q1 2010 vs. Q1 2009
Avastin	39%	52%	13%	25%
MabThera/Rituxan	25%	15%	-4%	27%
Herceptin	13%	21%	4%	12%
Tamiflu	1441%	3948%	762%	620%
Pegasys	15%	23%	-11%	36%
CellCept	2%	-7%	1%	5%
Xeloda	30%	10%	-8%	21%
NeoRecormon/Epogin	9%	5%	-24%	6%
Lucentis	-	-	-	-
Tarceva	31%	16%	2%	16%
Bonviva/Boniva	48%	27%	11%	33%
Valcyte/Cymevene	4%	-1%	10%	-1%
Xolair	-	-	-	-
Pulmozyme	17%	6%	-12%	78%
Activase/TNKase	0%	6%	0%	-24%
Xenical	-17%	-34%	-31%	-30%
Nutropin	0%	2%	-8%	-3%
Rocephin	8%	-5%	-23%	20%
Neutrogin	-	-	-	-
Madopar	-3%	10%	-1%	20%

7. Top 20 Pharmaceuticals Division quarterly product sales

CHF millions	Q1 2009	Q2 2009	Q3 2009	Q4 2009	Q1 2010
Avastin	1,485	1,605	1,594	1,538	1,666
MabThera/Rituxan	1,481	1,617	1,508	1,481	1,606
Herceptin	1,307	1,338	1,327	1,294	1,417
Tamiflu	401	609	994	1,196	517
Pegasys	393	449	438	375	441
CellCept	517	410	362	287	357
Xeloda	296	330	326	308	352
NeoRecormon/Epogin	378	411	391	380	339
Lucentis	279	294	296	329	327
Tarceva	320	323	319	342	326
Bonviva/Boniva	249	276	255	278	277
Valcyte/Cymevene	131	143	148	142	149
Xolair	152	161	157	150	148
Pulmozyme	120	128	125	128	135
Activase/TNKase	126	100	107	122	110
Xenical	103	106	98	90	91
Nutropin	104	107	100	89	91
Rocephin	77	87	73	70	82
Neutrogin	90	98	101	96	81
Madopar	68	72	71	75	75

8. Pharmaceuticals Division quarterly product sales United States

CHF millions	Q1 2009	Q2 2009	Q3 2009	Q4 2009	Q1 2010
Avastin	810	883	851	771	845
MabThera/Rituxan	769	809	734	703	763
Herceptin	390	420	397	359	408
Tamiflu	15	302	189	400	170
Pegasys	101	107	109	87	102
CellCept	256	140	119	34	83
Xeloda	106	118	131	118	123
NeoRecormon/Epogin	-	-	-	-	-
Lucentis	279	294	296	329	327
Tarceva	128	125	126	142	120
Bonviva/Boniva	137	154	132	148	144
Valcyte/Cymevene	60	72	77	66	70
Xolair	152	161	157	150	148
Pulmozyme	75	73	76	77	75
Activase/TNKase	114	90	96	111	100
Xenical	8	10	9	7	10
Nutropin	101	105	97	87	88
Rocephin	0	1	0	2	2
Neutrogin	-	-	-	-	-
Madopar	-	-	-	-	-

9. Pharmaceuticals Division quarterly product sales Western Europe

CHF millions	Q1 2009	Q2 2009	Q3 2009	Q4 2009	Q1 2010
Avastin	418	453	461	458	484
MabThera/Rituxan	395	419	421	408	442
Herceptin	517	533	547	528	570
Tamiflu	108	96	283	297	3
Pegasys	105	110	92	91	99
CellCept	119	127	123	125	123
Xeloda	75	79	80	77	81
NeoRecormon/Epogin	172	178	172	157	141
Lucentis	-	-	-	-	-
Tarceva	115	118	121	121	116
Bonviva/Boniva	72	74	77	81	79
Valcyte/Cymevene	39	41	41	43	46
Xolair	-	-	-	-	-
Pulmozyme	29	31	29	29	30
Activase/TNKase	-	-	-	-	-
Xenical	43	51	51	44	44
Nutropin	-	-	-	-	-
Rocephin	18	16	15	17	16
Neutrogin	-	-	-	-	-
Madopar	29	29	28	30	27

10. Pharmaceuticals Division quarterly product sales Japan

CHF millions	Q1 2009	Q2 2009	Q3 2009	Q4 2009	Q1 2010
Avastin	82	100	102	120	120
MabThera/Rituxan	52	63	62	67	53
Herceptin	81	93	83	88	67
Tamiflu	250	50	351	233	126
Pegasys	31	34	31	33	26
CellCept	11	13	13	14	12
Xeloda	15	18	19	25	27
NeoRecormon/Epogin	115	131	131	138	102
Lucentis	-	-	-	-	-
Tarceva	15	17	16	19	17
Bonviva/Boniva	-	-	-	-	-
Valcyte/Cymevene	-	-	-	-	-
Xolair	-	-	-	-	-
Pulmozyme	-	-	-	-	-
Activase/TNKase	-	-	-	-	-
Xenical	-	-	-	-	-
Nutropin	-	-	-	-	-
Rocephin	15	17	16	15	13
Neutrogin	90	98	101	96	81
Madopar	5	6	6	6	5

11. Pharmaceuticals Division quarterly product sales International

CHF millions	Q1 2009	Q2 2009	Q3 2009	Q4 2009	Q1 2010
Avastin	175	169	180	189	217
MabThera/Rituxan	265	326	291	303	348
Herceptin	319	292	300	319	372
Tamiflu	28	161	171	266	218
Pegasys	156	198	206	164	214
CellCept	131	130	107	114	139
Xeloda	100	115	96	88	121
NeoRecormon/Epogin	91	102	88	85	96
Lucentis	-	-	-	-	-
Tarceva	62	63	56	60	73
Bonviva/Boniva	40	48	46	49	54
Valcyte/Cymevene	32	30	30	33	33
Xolair	-	-	-	-	-
Pulmozyme	16	24	20	22	30
Activase/TNKase	12	10	11	11	10
Xenical	52	45	38	39	37
Nutropin	3	2	3	2	3
Rocephin	44	53	42	36	51
Neutrogin	-	-	-	-	-
Madopar	34	37	37	39	43